Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas - A prospective, randomized study

R. E. Rentschler; D. W. Wilbur; G. H. Petti; G. D. Chonkich; D. A. Hilliard; E. S. Camacho; R. B. Thorpe

doi:10.1200/JCO.1987.5.2.278

Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas - A prospective, randomized study

R. E. Rentschler, D. W. Wilbur, G. H. Petti, G. D. Chonkich, D. A. Hilliard, E. S. Camacho, R. B. Thorpe

Loma Linda University Medical Center

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	278-285
Number of pages	8
Journal	Journal of Clinical Oncology
Volume	5
Issue number	2
DOIs	https://doi.org/10.1200/JCO.1987.5.2.278
State	Published - Feb 1987

ASJC Scopus Subject Areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.1987.5.2.278License: Unspecified

OpenUrl availability

Full text

Cite this

@article{9930bff9601245729ca161fa1d84d723,

title = "Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas - A prospective, randomized study",

author = "Rentschler, {R. E.} and Wilbur, {D. W.} and Petti, {G. H.} and Chonkich, {G. D.} and Hilliard, {D. A.} and Camacho, {E. S.} and Thorpe, {R. B.}",

note = "To determine if adjuvant methotrexate (MTX), escalated weekly to toxicity, could improve disease-free survival (DFS) and overall survival by preventing recurrent disease, 60 patients with potentially resectable stage III or IV squamous head and neck carcinomas were stratified by primary site, stage, and nutritional status, then randomized by pairs to receive or not receive adjuvant MTX.",

year = "1987",

month = feb,

doi = "10.1200/JCO.1987.5.2.278",

language = "English",

volume = "5",

pages = "278--285",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

number = "2",

}

TY - JOUR

T1 - Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas - A prospective, randomized study

AU - Rentschler, R. E.

AU - Wilbur, D. W.

AU - Petti, G. H.

AU - Chonkich, G. D.

AU - Hilliard, D. A.

AU - Camacho, E. S.

AU - Thorpe, R. B.

N1 - To determine if adjuvant methotrexate (MTX), escalated weekly to toxicity, could improve disease-free survival (DFS) and overall survival by preventing recurrent disease, 60 patients with potentially resectable stage III or IV squamous head and neck carcinomas were stratified by primary site, stage, and nutritional status, then randomized by pairs to receive or not receive adjuvant MTX.

PY - 1987/2

Y1 - 1987/2

UR - http://www.scopus.com/inward/record.url?scp=0023112198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023112198&partnerID=8YFLogxK

U2 - 10.1200/JCO.1987.5.2.278

DO - 10.1200/JCO.1987.5.2.278

M3 - Article

SN - 0732-183X

VL - 5

SP - 278

EP - 285

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 2

ER -

Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas - A prospective, randomized study

ASJC Scopus Subject Areas

Access to Document

OpenUrl availability

Other files and links

Cite this